Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-15-Speech-2-600-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-02-15"^^xsd:date2
dcterms:Is Part Of	lp_eu:Question Time (Commission)2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20110215.30.2-600-000"2
lpv:hasSubsequent	lp_eu:2011-02-15-Speech-2-601-0002
lpv:speaker	lp:Marc Tarabella2
lpv:spokenAs	member; FEMM (2009-09-17--2012-01-18)3 member; S&D (2009-07-16--2014-06-30)3 member; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2010-07-07--2014-06-30)3 unknown; Parti Socialiste (2009-07-16--2014-06-30)3 substitute; Delegation for relations with the United States (2009-09-16--2014-06-30)3 member; AGRI (2009-09-16--2012-01-18)3 substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-10-07--2014-06-30)3 substitute; IMCO (2009-09-07--2012-01-18)3 member; Delegation for relations with the countries of Southeast Asia and the Association of Southeast Asian Nations (ASEAN) (2009-09-16--2014-06-30)3
lpv:translated text	"Madam President, Commissioner, let us extend the terms of this debate, because the Mediator product is simply the visible tip of the iceberg and raises a range of other questions. For example, how is it that a medicinal product that is considered to be potentially harmful, even fatal, and that has been withdrawn from the market in some Member States, can continue to circulate freely within the European Union? Should we not give serious thought to the role and the effectiveness of the European Medicines Agency, if its findings are not binding for Member States?"@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph